Compare Moderna, Inc. (MRNA) vs Solstice Advanced Materials Inc. Common Stock (SOLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Solstice Advanced Materials Inc. Common Stock — how do they compare? Moderna, Inc. trades at $223 (market cap $90.35B), while Solstice Advanced Materials Inc. Common Stock trades at $58.75 (market cap $9.55B). The key difference: Moderna, Inc. is far larger — about 9.5× Solstice Advanced Materials Inc. Common Stock's market cap, and Solstice Advanced Materials Inc. Common Stock pays a 0.5% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Solstice Advanced Materials Inc. Common Stock for 0 Days on average.
| MRNA | SOLS | |
|---|---|---|
Market Cap | $90.35B | $9.55B |
Volume | 16,579,584 | 2,661,277 |
Sector | Health | Basic Materials |
52-Week High | $226.30 | $88.60 |
52-Week Low | $22.36 | $41.43 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $86.50B | $11.23B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal as it joins the Nasdaq-100 index. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with negative net income margins (-142.58%) and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock has rallied over 500% in 2026, creating valuation concerns with a P/S ratio of 40.29.
While Nasdaq inclusion and cancer vaccine pipeline progress offer upside potential, Moderna's high valuation and persistent losses present significant risk. Analyst consensus is mixed with a $115.70 price target below current levels, indicating cautious sentiment despite recent momentum. Investors face tension between growth prospects and financial sustainability.
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Solstice Advanced Materials Inc. Common Stock
Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →
